References
- SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
- BensonAB3rdVenookAPBekaii-SaabTRectal cancer, Version 2.2015J Natl Compr Canc Netw2015136719728 quiz 72826085388
- MengXHuangZTengFXingLYuJPredictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapyCancer Treat Rev2015411086887626589760
- RiellaLVPatersonAMSharpeAHChandrakerARole of the PD-1 pathway in the immune responseAm J Transplant201212102575258722900886
- KeirMEButteMJFreemanGJSharpeAHPD-1 and its ligands in tolerance and immunityAnnu Rev Immunol20082667770418173375
- DongHStromeSESalomaoDRTumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasionNat Med20028879380012091876
- IkedaSOkamotoTOkanoSPD-L1 is upregulated by simultaneous amplification of the PD-L1 and JAK2 genes in non-small cell lung cancerJ Thorac Oncol2016111627126762740
- IlieMHofmanVDietelMSoriaJCHofmanPAssessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patientsVirchows Arch2016468551152526915032
- KhalilDNSmithELBrentjensRJWolchokJDThe future of cancer treatment: immunomodulation, CARs and combination immunotherapyNat Rev Clin Oncol201613527329026977780
- BarkerHEPagetJTKhanAAHarringtonKJThe tumour microenvironment after radiotherapy: mechanisms of resistance and recurrenceNat Rev Cancer201515740942526105538
- HeriotAGKumarDAdjuvant therapy for resectable rectal and colonic cancerBr J Surg19988533003099529480
- DengLLiangHBurnetteBIrradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in miceJ Clin Invest2014124268769524382348
- OhigashiYShoMYamadaYClinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancerClin Cancer Res20051182947295315837746
- TamuraTOhiraMTanakaHProgrammed death-1 ligand-1 (PDL1) expression is associated with the prognosis of patients with stage II/III gastric cancerAnticancer Res201535105369537626408698
- ShimojiMShimizuSSatoKClinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)Lung Cancer201698697527393509
- HamanishiJMandaiMIwasakiMProgrammed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancerProc Natl Acad Sci U S A200710493360336517360651
- DroeserRAHirtCViehlCTClinical impact of programmed cell death ligand 1 expression in colorectal cancerEur J Cancer20134992233224223478000
- LeeLHCavalcantiMSSegalNHPatterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinomaMod Pathol201629111433144227443512
- SaigusaSToiyamaYTanakaKImplication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapyInt J Clin Oncol201621594695226919982
- RehmanJAHanGCarvajal-HausdorfDEQuantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancerMod Pathol201730334034927834350
- ChenJJiangCCJinLZhangXDRegulation of PD-L1: a novel role of pro-survival signalling in cancerAnn Oncol201627340941626681673
- ShahabiVPostowMATuckDWolchokJDImmune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacyAm J Clin Oncol2015381909725616204
- HechtMButtner-HeroldMErlenbach-WunschKPD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosisEur J Cancer201665526027468145
- KimJHParkHEChoNYLeeHSKangGHCharacterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancersBr J Cancer2016115449049627404452
- MeiZLiuYLiuCTumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysisBr J Cancer201411061595160524504370